**CardioFlow**

**Self-Expanding Proximal Embolic Protection Device**

Eighty million Americans have cardiovascular disease. Many undergo vascular interventions, such as angioplasty and stenting, mainly for opening blocked arteries. During such procedures, microparticles of plaque and clot may dislodge from the treated lesion and flow downstream within the blood. This can lead to microvascular obstruction, a serious complication that can result in myocardial infarction (heart attack), heart or renal failure, limb amputation, and death.

**THE PRODUCT**

CardioFlow has developed EmboPRO™, a device that prevents microparticles from reaching and obstructing vessels by occluding blood flow proximal to the treated lesion and aspirating the microparticles.

EmboPRO is made of super-elastic nitinol and employs a unique self-expanding mechanism for achieving flow occlusion. It is suitable for use in a range of procedures such as coronary angioplasty and stenting as well as angioplasty and stenting in renal and peripheral vessels.

**THE ADVANTAGES**

EmboPRO’s self-expanding occlusion mechanism combines effective protection with maximum simplicity.

- Obviates disadvantages of distal filters and proximal balloons
- Simple stand-alone add-on to existing equipment
- Minimal change to standard interventional procedure
- Rapid vessel occlusion and flow control for reduced ischemia

**THE MARKET**

CardioFlow will initially target coronary bypass graft (SVG) interventions, which represent approximately 10% of the total percutaneous coronary interventions\(^1\), or 240,000 U.S. and European procedures annually.

The overall market for embolic protection devices is expected to reach over $500 million by 2015\(^2\), a significant market opportunity for CardioFlow’s EmboPRO.

**FUNDING**

CardioFlow seeks follow-on investment of **$1 million** required for conducting clinical trials and submitting data for EmboPRO to support CE mark approval by the end of 2013.

---

1 Lee et al., JACC 2011, 4:831-843.